We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

142 hedge funds and large institutions have $428M invested in Progenics Pharmaceuticals Inc in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 55 increasing their positions, 41 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 41

0% more capital invested

Capital invested by funds: $426M → $428M (+$2.07M)

7% less funds holding

Funds holding: 152 → 142 (-10)

35% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 23

35% less call options, than puts

Call options by funds: $1.81M | Put options by funds: $2.78M

Holders
142
Holders Change
-10
Holders Change %
-6.58%
% of All Funds
3.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
15
Increased
55
Reduced
41
Closed
23
Calls
$1.81M
Puts
$2.78M
Net Calls
-$973K
Net Calls Change
-$607K

Top Buyers

Rank Fund Capital Flow
1
AAP
Ardsley Advisory Partners
Connecticut
+$8.89M
2
BlackRock
BlackRock
New York
+$1.3M
3
HP
Hikari Power
Japan
+$1.27M
4
TCIM
TIAA CREF Investment Management
New York
+$1.21M
5
Bank of America
Bank of America
North Carolina
+$1.1M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$6.79M
2
PWAM
Park West Asset Management
California
-$6.16M
3
Wellington Management Group
Wellington Management Group
Massachusetts
-$3.54M
4
Invesco
Invesco
Georgia
-$3.34M
5
State Street
State Street
Massachusetts
-$2.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
PFC
126
Phocas Financial Corp
California
$11K +$213K +33,537 +2%
RFA
127
Reilly Financial Advisors
California
$10K – – –
LJHT
128
Laurie J. Hall Trustee
$6.77K – – –
MAM
129
Meeder Asset Management
Ohio
$5K +$19 +3 +0.4%
AG
130
Advisor Group
Arizona
$4K -$43.6K -6,872 -93%
PNC Financial Services Group
131
PNC Financial Services Group
Pennsylvania
$3K -$337 -53 -12%
IA
132
IFP Advisors
Florida
$3K – – –
MA
133
MUFG Americas
New York
$2K – – –
AFNAS
134
American Financial Network Advisory Services
California
$2K +$1.4K +220 New
KF
135
Krilogy Financial
Missouri
$2K +$1.91K +300 New
AIM
136
Advantage Investment Management
Iowa
$1K – – –
AssetMark Inc
137
AssetMark Inc
California
$1K +$1.27K +200 New
BC
138
Broadfin Capital
New York
– -$6.79M -1,000,000 Closed
PWAM
139
Park West Asset Management
California
– -$6.16M -907,351 Closed
Wellington Management Group
140
Wellington Management Group
Massachusetts
– -$3.54M -521,025 Closed
Renaissance Technologies
141
Renaissance Technologies
New York
– -$1.98M -291,489 Closed
IG
142
ING Group
Netherlands
– -$1.36M -200,000 Closed
MWNA
143
Marshall Wace North America
New York
– -$1.14M -162,869 Closed
GCP
144
GSA Capital Partners
United Kingdom
– -$983K -144,743 Closed
QIM
145
Quantitative Investment Management
Virginia
– -$858K -126,400 Closed
Millennium Management
146
Millennium Management
New York
– -$624K -91,911 Closed
TC
147
TFS Capital
Pennsylvania
– -$531K -78,134 Closed
SCM
148
Stevens Capital Management
Pennsylvania
– -$372K -54,771 Closed
FRM
149
Fox Run Management
Connecticut
– -$335K -49,300 Closed
MLICM
150
Metropolitan Life Insurance Company (MetLife)
New York
– -$328K -48,263 Closed
3 4 5
6
7

PGNX Hedge Fund Activity: Q3 2017 in Review

142 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2017, worth a combined $428M — up 0.49% from $426M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of PGNX and 15 opened new positions — a net loss of 8 holders — while 41 trimmed existing stakes and 55 added.

The largest buyer was Ardsley Advisory Partners, adding an estimated $8.89M. The largest seller was Broadfin Capital, exiting entirely with an estimated $6.79M sold.

  • 142 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2017, down from 152 in Q2 2017.
  • Funds reported $428M of Progenics Pharmaceuticals Inc stock for Q3 2017, up 0.49% quarter-over-quarter.
  • 15 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2017 and 23 closed out, a net change of -8 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2017 was Ardsley Advisory Partners, an estimated $8.89M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2017 was Broadfin Capital, an estimated $6.79M sold.

Based on aggregated 13F filings for Q3 2017.